Stephen Samuel Weigt, MD
Pulmonary Disease · Los Angeles, CANPI 1063617116
Payments from drug & device makers
Across 524 payments — averaging $4045.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$996K
- Boehringer Ingelheim$844K
- Sanofi US Services Inc.$142K
- Roche Products Limited$44K
- Incyte Corporation$40K
- Boehringer Ingelheim International GmbH$17K
- plus $37K from 10 others
Across 5 payments — averaging $2562.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$13K
- Sanofi-aventis U.S. LLC$90
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 126 | $995,675 |
| Boehringer Ingelheim | 107 | $844,167 |
| Sanofi US Services Inc. | 17 | $142,199 |
| Roche Products Limited | 3 | $44,162 |
| Incyte Corporation | 48 | $39,961 |
| Boehringer Ingelheim International GmbH | 85 | $16,828 |
| Mallinckrodt Enterprises LLC | 1 | $10,495 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 65 | $8,258 |
| Zambon USA Ltd. | 13 | $7,104 |
| Mallinckrodt Hospital Products Inc. | 2 | $5,725 |
| Boehringer Ingelheim France S.a.s. | 37 | $3,690 |
| Boehringer Ingelheim Limited | 10 | $1,107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $192 |
| Genentech USA, Inc. | 3 | $164 |
| Genentech, Inc. | 2 | $71 |
| Gilead | 1 | $37 |
How this compares
$2,119,834 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$27.6M
- Andrew WachtelLos Angeles$5.9M
- Michael RothLos Angeles$4.5M
- Rajan SaggarLos Angeles$3.3M
- Robert WolfeLos Angeles$1.9M
- Igor BarjaktarevicLos Angeles$1.9M
- Shelley ShapiroLos Angeles$1M
- Victor TapsonLos Angeles$931K
- John BelperioLos Angeles$905K
- Sivagini GaneshLos Angeles$816K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.